Regresar

Polymorphic oxidation of debrisoquine in lung cancer patients

Abstract:

Oxidative polymorphism of debrisoquine (DBQ) was assessed in 84 patients (81 male) with histologically proven bronchogenic carcinoma and in 143 healthy male smokers. 80 (95%) patients and 133 (93%) controls, with a metabolic ratio (MR) below 12.6, were classified as extensive metabolisers of DBQ (no significant difference between patients and controls). Only 1 of the 73 patients with epidermoid or microcytic carcinomas was classified as a poor metaboliser (PM) (P = 0.031 compared with controls). 63 patients (75%) and 110 controls (77%) showed a very fast oxidative rate, with MR values under 1 (not significant). The EM phenotype of DBQ might be a secondary genetic risk factor for developing bronchogenic carcinoma in male smokers. © 1991.

Año de publicación:

1991

Keywords:

    Fuente:

    scopusscopus

    Tipo de documento:

    Article

    Estado:

    Acceso restringido

    Áreas de conocimiento:

    • Farmacología
    • Farmacología
    • Farmacología

    Áreas temáticas:

    • Enfermedades
    • Farmacología y terapéutica

    Contribuidores:

    Jara C.Jara C.
    Benitez Rodriguez J.Benitez Rodriguez J.
    Adrián LLerenaAdrián LLerena
    Vargas E.Vargas E.
    Muñoz J.J.Muñoz J.J.
    Carrillo J.A.Carrillo J.A.
    Cobaleda J.Cobaleda J.
    Ladero J.M.Ladero J.M.